Austrian Biotech Startup LifeTaq Files for Insolvency After Animal Testing Breakthroughs

LifeTaq, an Austrian biotech startup, has filed for insolvency in Klosterneuburg. The company specialized in creating fully automated 3D tissue models to replace animal testing in drug research. Despite ambitious plans and significant funding, its financial struggles have led to bankruptcy proceedings.

Founded with the goal of reducing animal testing, LifeTaq developed a machine designed to culture 3D tissue models automatically. This technology aimed to provide a more ethical and scientifically reliable method for drug research. The company secured €3.5 million in public funding from the Austrian Research Promotion Agency (FFG) and ran a successful crowdfunding campaign on Rockets, raising over €300,000.

LifeTaq had projected profitability by selling just four of its machines, with expected earnings of up to €4 million by 2027. However, its financial position weakened over time. Despite the funding and early support, the company's deteriorating finances forced it to file for insolvency.

The future of LifeTaq's technology and remaining assets remains unclear. Competitors or investors may acquire them, but no decisions have been announced yet.

The insolvency filing marks the end of LifeTaq's operations in its current form. The company's focus on replacing animal testing with automated 3D tissue models had attracted public and private backing. Now, the fate of its technology and intellectual property will depend on potential buyers or restructuring efforts.